Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 5Terminated 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 7Thoracic 5Gynecologic 5CNS 4Head & Neck 3Sarcoma 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 3Triple Negative Breast Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × adavosertib × Thoracic × Clear all
NCT02513563 2026-02-19

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
42 enrolled 12 charts
Thoracic

Lung Neoplasms

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

AstraZeneca

Phase 2 Completed
72 enrolled 29 charts
Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02593019 2021-03-19

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Samsung Medical Center

Phase 2 Completed
24 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02511795 2019-11-07

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

AstraZeneca

Phase 1 Completed
128 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡